Monday, 17 June 2019

DelSiTech gets fund for contraceptives and HIV antiviral injectables

21 May 2019 | News

The funds are received from the Bill & Melinda Gates Foundation

DelSiTech Ltd, a drug delivery and drug development company based in Finland announced significant grant funding to support the development of long-acting controlled release formulations for family planning as well as for human immunodeficiency virus (HIV) antivirals, from the Bill & Melinda Gates Foundation.

DelSiTech is the global leader in advanced silica-based, sustained and controlled release delivery technologies for administration of injectable, implant and topical eye drop dosage forms. Its technology offers long-acting injectable medical solutions to enable longer treatment periods and fewer injections.

DelSiTechTM Silica Matrix technology allows the drug substances, ranging from small molecules to biologics to be encapsulated in matrix microparticles, providing stability for the drug substance and a true controlled long-acting release based on the matrix dissolution. This allows the injection to release a stabilized product for months or over a year.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account